Aurobindo-Lannett, In the Matter of
No reply on file from Aurobindo-Lannett on this matter.
Claims entered
No claim has been entered on this docket.
1 filed · 1 on the record. The chronology below carries every filing, docket event and outcome — open a row there for its source.
Open to posting — anyone may add to this file, subject to the review queue.
The chronology
Gov, Institution and Public name who produced a document; Event marks a thing that happened, not a document.
1 entry of another class is hidden by this filter — show every class.
By when it happened. Rows with no date on their face are shown as undated, not guessed. Hover, focus or tap a row for its full detail.
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
No crime, statute, place, status, party or amount is on the record for this docket yet.